Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

19.28
-0.2000-1.03%
Post-market: 19.280.00000.00%16:11 EDT
Volume:44.96K
Turnover:863.84K
Market Cap:983.93M
PE:-8.23
High:19.48
Open:19.22
Low:18.98
Close:19.48
Loading ...

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

GlobeNewswire
·
01 Apr

Lumentum to Showcase Cutting-Edge Optical Innovations for Cloud, AI, and Networking Infrastructure at OFC 2025

Business Wire
·
28 Mar

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

PR Newswire
·
26 Mar

1 Compelling Reason to Buy and Hold TransMedics Group Stock Forever

Motley Fool
·
22 Mar

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

GlobeNewswire
·
21 Mar

Lionel Carnot Spends CHF326k On Oculis Holding Stock

Simply Wall St.
·
19 Mar

1 Turnaround Growth Stock Down 60% That Could Double, According to Wall Street

Motley Fool
·
19 Mar

Coherent Introduces 2D Collimator Array for Optical Circuit Switches

GlobeNewswire
·
18 Mar

Oculis Holding’s Promising Pipeline and Strategic FDA Alignments Support Buy Rating

TIPRANKS
·
17 Mar

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
15 Mar

Oculis Holding Price Target Raised to $41.00/Share From $37.00 by Baird

Dow Jones
·
13 Mar

Oculis price target raised to $41 from $37 at Baird

TIPRANKS
·
13 Mar

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
13 Mar

Oculis Holding Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
13 Mar

Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions

TIPRANKS
·
13 Mar

Oculis Holding AG Reports 2024 Financial Results

TIPRANKS
·
13 Mar

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
12 Mar

Oculis Holding Q4 EPS $(0.67) Misses $(0.44) Estimate

Benzinga
·
12 Mar

Press Release: Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Dow Jones
·
12 Mar

Down 62%. Should You Buy TransMedics Stock on the Dip?

Motley Fool
·
11 Mar